ArticleEuropean radiology2026
Staging of non-metastatic nasopharyngeal carcinoma with PET/CT.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
objectivesTo evaluate the prognostic accuracy and clinical applicability of the ninth edition of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) tumor-node-metastasis (TNM) staging system for non-metastatic nasopharyngeal carcinoma (NPC) in the era of [ MATERIALS AND
methodsThis retrospective study included 301 patients with NPC treated by intensity-modulated radiotherapy at a tertiary academic cancer center from January 1, 2003, to February 28, 2023. The comparison between the ninth edition of the AJCC/UICC TNM (TNM-9) and the eighth edition of the AJCC/UICC TNM (TNM-8) staging systems was performed. The primary endpoint was overall survival (OS).
resultsThe proportions of patients receiving [
conclusionThe TNM-9 staging system did not exhibit strong overall discrimination between the stage-group classifications for OS of non-metastatic NPC in the [ KEY POINTS: Question Does the newly launched TNM-9 staging system (January 2025) remain valid for non-metastatic NPC in the era of [
Indexed as
Identifiers
42009870What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.